SCHEDULE 13G/A 0000902664-24-006564 0001974915 XXXXXXXX LIVE 2 Common Stock, par value $0.001 per share 12/31/2025 0001454789 Astria Therapeutics, Inc. 04635X102 22 BOSTON WHARF ROAD 10TH FLOOR BOSTON MA 02210 Rule 13d-1(b) Vestal Point Capital, LP DE 0.00 0.00 0.00 0.00 0.00 N 0 IA PN Ryan Wilder X1 0.00 0.00 0.00 0.00 0.00 N 0 HC IN Astria Therapeutics, Inc. 22 BOSTON WHARF ROAD, 10TH FLOOR, BOSTON, MA, 02210 This statement is filed by: (i) Vestal Point Capital, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to a certain fund and a managed account (the "Vestal Point Fund and Account"), with respect to the shares of common stock, par value $0.001 per share (the "Common Stock"), of Astria Therapeutics, Inc. (the "Company") directly held by the Vestal Point Fund and Account; and (ii) Mr. Ryan Wilder ("Mr. Wilder"), the Chief Investment Officer and Managing Partner of the Investment Manager and the Managing Member of Vestal Point Capital, LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Vestal Point Fund and Account. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein. The address of the business office of each of the Reporting Persons is 632 Broadway, Suite 602, New York, NY 10012. The Investment Manager is a Delaware limited partnership. Mr. Wilder is a citizen of the United States. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. 0% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Vestal Point Capital, LP /s/ Ryan Wilder 02/17/2026 Ryan Wilder /s/ Ryan Wilder 02/17/2026